Stockreport

DMD clinical studies evolve with emphasis on building designs around relevant endpoints [Yahoo! Finance]

Capricor Therapeutics, Inc.  (CAPR) 
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: capricor.com/investors
PDF in Duchenne muscular dystrophy (DMD) indicates that choosing the right trial endpoint remains an evolving paradigm. Experts say it is notoriously difficult to evaluate [Read more]